The New Audi A6 Plug-In Hybrid Has a Decent Electric Range
These upscale PHEVs can travel up to 66 miles (106 kilometers) on a single charge in the combined cycle before the combustion engine kicks in. Stick with the slightly lighter sedan, and
Audi
says you can get up to 69 miles (111 kilometers) in the city. The quickest way to deplete the battery, mounted under the rear section, is to drive on the Autobahn at the electronically limited 87 mph (140 km/h) in EV mode. With the engine running, the plug-in hybrid A6 can hit 155 mph (250 km/h).
Photo by: Audi
Two versions are available: one with 295 hp and another with 362 hp. If those figures sound familiar, it's because the
new A5 plug-in hybrid
has identical outputs. The two models are closely related, both riding on the Premium Platform Combustion. Logic tells us that PPC could also underpin Porsche's upcoming
gas-powered Macan successor
, which is expected later this decade.
The base A6 PHEV makes 332 lb-ft (450 Nm) of torque and does 0–62 mph (100 km/h) in six seconds flat. Step up to the more powerful version and get 369 lb-ft (500 Nm) and a sprint time of just 5.3 seconds. If you want something quicker, a V-6 3.0-liter mild-hybrid model does the job in 4.7 seconds. Of course, the upcoming S6 and RS6 will be even faster.
The plug-in hybrid is the wise choice for those prioritizing efficiency and want to move on from diesel. Audi has increased AC charging capacity to 11 kW, enabling a full charge in just two and a half hours. Both PHEVs have rear-wheel steering, a dual-clutch automatic transmission, and Quattro all-wheel drive. The 141-horsepower electric motor is integrated into the seven-speed S Tronic gearbox's housing. Audi says full torque is available 'at close to idle speed,' helping these models get off the line effortlessly.
2026 Audi A6 plug-in hybrid
31
Source: Audi
The electrified A6 is significantly quieter than its predecessor, thanks to a 30 percent increase in sound insulation. The same improvements apply to conventionally powered versions, which now get acoustic glazing on the rear-side windows and tighter door and window seals. Additional noise reduction comes from foam rings in the tires on cars equipped with 19-inch wheels and larger. Audi also reworked the engine and transmission mount bushings and optimized the shape of the gear teeth to reduce mechanical noise.
In Germany, the A6 Sedan E-Hybrid starts at €65,800 for the base model and from €68,300 for the more powerful version. The more practical A6 Avant E-Hybrid begins at €75,050 and €77,550, respectively. That price gap between the two power levels also reflects added standard equipment like S Line trim inside and out, larger wheels, a sport suspension, and red brake calipers. Deliveries in Europe begin this summer.
Keep Up With Audi:
The New Audi RS5 Sounds Pretty Darn Good
Audi Will Launch an Entry-Level Electric Car in 2026
Get the best news, reviews, columns, and more delivered straight to your inbox, daily.
back
Sign up
For more information, read our
Privacy Policy
and
Terms of Use
.
Source:
Audi
Share this Story
X
Got a tip for us? Email:
tips@motor1.com
Join the conversation
(
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Electric vehicle sales growth eases to 21% in July, research firm says
By Alessandro Parodi (Reuters) -Global electric vehicle sales grew 21% year-on-year in July, the slowest rate since January and down from 25% in June, as momentum in plug-in hybrid sales in China slackened, market research firm Rho Motion said on Wednesday. WHY IT'S IMPORTANT China is the world's biggest car market and accounts for more than half of global EV sales, which in Rho Motion's data include battery-electric vehicles and plug-in hybrids. Switch Auto Insurance and Save Today! Great Rates and Award-Winning Service The Insurance Savings You Expect Affordable Auto Insurance, Customized for You Its overall car sales growth slowed in July, with BYD, the world's largest EV maker, recording its third monthly drop in registrations. The relatively muted slowdown in overall EV sales however shows other markets are taking up some of the slack, with European sales for one benefiting from incentives aimed at speeding up decarbonisation. BY THE NUMBERS Global sales of battery-electric vehicles and plug-in hybrids rose to 1.6 million units in July, Rho Motion data showed. China's EV sales growth, which averaged 36% a month in the first half, eased to 12% in July as the previously booming market was dampened by a pause in some 2025 government subsidy schemes for EV and plug-in hybrid purchases, Rho Motion data manager Charles Lester said. Chinese sales reached around one million vehicles. European sales surged 48% to about 390,000 units, while North American sales climbed 10% to more than 170,000. Sales in the rest of the world jumped 55% to more than 140,000 vehicles. KEY QUOTE "Despite regional variations, the overall trajectory for EV adoption in 2025 remains strongly upward," Lester said. WHAT'S NEXT Chinese car sales are expected to return to strong growth from August as new funds become available for its subsidy schemes, while a cut in U.S. tax credits for buying or leasing new EVs at the end of September will hurt demand there, Lester added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN, August 12, 2025--(BUSINESS WIRE)--Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: "Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes." Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: "Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD." Elaine Mac Hale, Clinical Operations Director, added: "Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care." Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise. View source version on Contacts phyxiom@ or call Lewis Oakley or Kirsty Leighton on +44 20 3637 7310 Sign in to access your portfolio
Business Insider
18 minutes ago
- Business Insider
TSLA vs. AAPL vs. MSFT: Which Magnificent 7 Stock Is Wall Street's Best Pick?
The Magnificent 7 stocks: Alphabet (GOOGL), Amazon (AMZN), Apple (AAPL), Meta Platforms (META), Microsoft (MSFT), Nvidia (NVDA), and Tesla (TSLA) are prominent tech companies that are known for their market dominance, innovation, and influence on the NASDAQ and S&P 500 (SPX) indices. Using TipRanks' Stock Comparison Tool, we placed three of the Magnificent 7 stocks – Tesla, Apple, and Microsoft against each other to pick the best stock, according to Wall Street analysts. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tesla (NASDAQ:TSLA) Stock Shares of electric vehicle (EV) Tesla have advanced about 10% over the past month, but are still down about 16% year-to-date. Tesla bulls are confident about the company's ability to navigate short-term challenges and capture opportunities in the full self-driving (FSD), robotaxi, and robotics areas. However, some analysts are concerned about persistent weakness in Tesla's deliveries due to intense competition and macro woes, disappointing financials, backlash associated with Musk's political activities, and loss of EV credits. Overall, Tesla needs to revive its core auto business and win back investors' confidence by improving its financials and capturing opportunities in growth areas like robotaxis. What Is the Price Target for Tesla Stock? Recently, Wolfe Research analyst Emmanuel Rosner reiterated a Hold rating on Tesla stock. Rosner noted TSLA stock's underperformance compared to the broader market on a year-to-date basis. The analyst believes that near-term, Street estimates still appear high, especially for 2025 and 2026. He expects Tesla's free cash flow to remain under pressure, with strong growth in the company's 'burgeoning Energy business a key swing factor.' However, Rosner thinks that Tesla trades more around the narrative than the numbers, and net-net, he 'tactically' expects an improving narrative from here. He noted that Tesla has several catalysts coming, including FSD and robotaxi, as well as an expansion of the company's autonomous vehicle (AV) service into several new U.S. markets, such as San Francisco, Nevada, and Arizona. Rosner also noted Tesla's other growth initiatives, including the launch of supervised FSD in China and Europe over the next 12 months and the expansion of Optimus production in 2026. Overall, Wall Street has a Hold consensus rating on Tesla stock based on 14 Buys, 15 Holds, and eight Sell recommendations. The average TSLA stock price target of $307.23 indicates a possible downside of 9.4% from current levels. Apple (NASDAQ:AAPL) Stock iPhone maker Apple recently reported better-than-expected results for the third quarter of Fiscal 2025 (June quarter). Notably, iPhone sales jumped 13% and Apple's overall revenue rose 10%, marking the company's largest quarterly top-line growth since December 2021. The tech giant expects its overall revenue growth in the September quarter to be in the mid- to high-single-digit range, with services expected to increase at a similar rate to Q3 FY25's 13% year-over-year growth. Apple stock has risen about 12% over the past five trading sessions, as investors cheered CEO Tim Cook's recent meeting with President Donald Trump to announce the company's plans to invest $100 billion in America over the next four years. This brings Apple's total commitment to $600 billion. The move pleased President Trump, who announced that Apple would be exempt from future tariffs that could double the price of imported chips. However, AAPL stock is still down 9.3% year-to-date, as investors are concerned about the company falling behind in the AI race and intense competition in the smartphone market. Is Apple a Buy, Sell, or Hold? Following the announcement of Apple's increased investment in the U.S., Bank of America Securities analyst Wamsi Mohan increased the price target for AAPL stock to $250 from $240 and reaffirmed a Buy rating. The 5-star analyst stated that Apple's increased investments in the U.S. could result in several of its products being exempted from tariffs. Furthermore, Mohan believes there is the potential for Apple to gain smartphone market share in the U.S. if competitors are subjected to tariffs while iPhones remain exempt. He expects Apple's gross margin to gain from potential tariff relief, with the December quarter gross margin expected to benefit from forex-related tailwinds as well. Mohan stated that he now has increased confidence in Apple's EPS to be more than $8 in calendar year 2026. Mohan assigned a higher multiple to Apple stock to reflect increased optimism about the company's profitability from supply chain investments. He remains bullish on AAPL stock due to stable cash flows, earnings resiliency, and a solid capital returns program. Wall Street has a Moderate Buy consensus rating on Apple stock based on 16 Buys, 12 Holds, and one Sell recommendation. The average AAPL stock price target of $235.14 indicates 3.5% upside potential. Microsoft (NASDAQ:MSFT) Stock Microsoft stock has risen about 24% year-to-date, as investors are upbeat about the company's growth potential and AI-led growth in the Azure cloud business. The company's significant investments are helping to capture the robust demand for AI infrastructure. Notably, Microsoft recently reported impressive results for the fourth quarter of Fiscal 2025, thanks to demand for cloud services and AI strength. Notably, revenue from Microsoft Azure and other cloud services grew 39% (at constant currency). In fact, Azure revenue rose 34% to surpass $75 billion in the full year. Looking ahead, the company is poised to gain from the generative AI boom. Is Microsoft a Buy, Hold, or Sell? Impressed by the Q4 print, Cantor Fitzgerald analyst Thomas Blakey increased the price target for Microsoft stock to $639 from $581 and reiterated a Buy rating. The 4-star analyst noted that the fiscal fourth quarter witnessed demand acceleration. Blakey highlighted that demand continued to outstrip supply for cloud services, with the equilibrium once expected for the end of Fiscal 2025 pushed out to the end of calendar 2026. He added that Azure's solid performance was driven by Microsoft's largest customers' core infrastructure business as new cloud and AI workloads are built and scale across services. He pointed out Microsoft's commentary about migrations remaining strong as customers increased modernization efforts, likely related to AI. With 34 Buys versus one Hold recommendation, Microsoft scores a Strong Buy consensus rating on TipRanks. The average MSFT stock price target of $623.34 indicates 19.5% upside potential from current levels. Conclusion Wall Street is highly bullish on Microsoft stock, cautiously optimistic on Apple stock, and sidelined on Tesla stock. Analysts see higher upside potential in MSFT stock than in the other two Magnificent 7 stocks discussed here. Wall Street is optimistic about Microsoft due to its diversified business model and robust demand for cloud computing and AI tools. Microsoft is well-positioned to deliver solid growth and impressive margins.
